Samsung vs. Oura Health: Wearable Patent Dispute Ends in Voluntary Dismissal

Case Overview

In one of the more closely watched wearable technology patent disputes of 2025, Samsung Group and Finnish health-tech innovator Oura Health Oy reached a mutual agreement to dismiss their Federal Circuit appeal — closing Case No. 25-1871 in just 58 days. The proceeding, which centered on five U.S. patents covering heart rate monitoring, blood oxygen sensing, sleep tracking, and movement analysis, had implicated some of Samsung’s most commercially significant wearable products, including the Galaxy Watch series, the Samsung Health app, and the strategically important Galaxy Ring.

The voluntary dismissal — ordered under Fed. R. App. P. 42(b) with each party bearing its own costs — signals a negotiated resolution rather than a decisive judicial ruling. For patent attorneys tracking **wearable technology patent infringement** trends, IP professionals monitoring the smart ring and biosensor space, and R&D teams navigating freedom-to-operate risk, this case offers meaningful signals about how high-stakes patent disputes in consumer health technology are being resolved outside the courtroom.

The Parties

Patents at Issue

Five U.S. patents were asserted in this proceeding:

• • US10893833B2 — Physiological signal monitoring (heart rate, SpO2)
• • US11868178B2 — Movement detection and sleep stage analysis
• • US11868179B2 — Heart rate variability (HRV) analysis systems
• • US11599147B2 — Advanced biosensor integration in wearables
• • US10842429B2 — Data processing for health metrics from wearables

These patents collectively cover wearable-device technologies related to **physiological signal monitoring** — specifically heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), movement detection, and sleep stage analysis. In plain terms, the asserted claims cover the core sensing and algorithmic infrastructure that makes a smart ring or smartwatch a health device rather than a simple timepiece.

The Verdict & Legal Analysis

Outcome

The Court of Appeals for the Federal Circuit dismissed Case No. 25-1871 on August 15, 2025, pursuant to **Federal Rule of Appellate Procedure 42(b)**, upon stipulation of the parties. Each side was ordered to bear its own costs. No damages were awarded, and no injunctive relief was granted or denied by the appellate court. The specific financial or licensing terms of any underlying settlement were not disclosed in the public record.

Legal Significance

Because the case terminated by voluntary dismissal without a merits ruling, it does not establish binding precedent on claim construction, infringement standards, or validity of the five asserted patents. The patents remain in force. However, the case illustrates an important strategic reality in **wearable technology patent litigation**: when asserted patents cover the core functionality of a market-defining product, both plaintiffs and defendants face significant risk calculus that often favors negotiated resolution over appellate adjudication.